Source: CureToday articles
The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.
Recent Content
- ASCO 2025: Evaluating Nivolumab Plus Relatlimab in Resected Stage 3 or 4 Melanoma
- Clesrovimab Receives FDA Approval for RSV Lower Respiratory Tract Prevention in Infants
- I Sometimes Forget to Celebrate Survivorship
- Policy Shifts Ahead: Expert Reviews Key Legislative Trends Reshaping Health-System Pharmacy
- A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma
- Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC
- You Are Not Alone While Building a Support Team During Cancer Care
- Community Pharmacist Collaboration Expands Access to Long-Acting Injectable Antipsychotics
- Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma
- ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma